Loading…
Cibus, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.1% over 5Y.
today you would have $9.02▼ -99.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.74 | $2.78 | $19.64 | $7.40 | |
| P/S | 36.0x | 26.0x | 18.2x | 222.3x | 46.0x |
| P/B | 1.2x | 4.3x | 0.8x | 1.4x | 1.0x |
| EPS | -$2.78 | -$10.83 | -$25.95 | -$18.50 | |
| Profit margin | -8328.48% | -3492.31% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AARDAardvark Therapeutics, Inc. | $5.79 | — | 1.7x | — | -66.02% | $126.71M |
| CPIXCumberland Pharmaceuticals Inc | $8.46 | — | 7.3x | — | -14.39% | $126.76M |
| BMEABiomea Fusion, Inc. | $1.73 | — | 10.4x | — | -164.14% | $125.08M |
| BDTXBlack Diamond Therapeutics, Inc. |
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Company description provided by Yahoo Finance.
| -5898.36% |
| -14729.06% |
| -10758.60% |
| ROE | -253.15% | -582.18% | -272.78% | -91.19% | -233.53% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| $2.23 |
| — |
| 1.3x |
| — |
| -37.22% |
| $127.78M |
| VTVTvTv Therapeutics Inc. | $32.36 | — | 5.1x | — | -15.80% | $127.95M |
| MXCTMaxcyte Inc | $1.24 | — | 0.8x | — | -20.39% | $127.98M |